The sensitivity of the NF1-kd endothelial cell proliferation and the normalization of the vascular morphogenesis following treatment with low-dose rapamycin in our assays suggest that “Rapalogs” currently in clinical trials as anti-tumor medications may be an effective management tool for certain types of vascular dysfunction in NF1 patients. The gene discussed is NF1; the disease is neoplasm.